CFDA Said Considering Shortening Oncology Drug INDs To 60 Days
This article was originally published in PharmAsia News
In one reform after another, the China FDA is acting swiftly to accelerate new drug approvals, this time with a focus on innovative cancer therapies. The agency is said to be planning a pilot scheme that would change the current investigational new drug (IND) process from an approval to a filing mechanism, and set 60 days as the timeframe.
You may also be interested in...
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
With gene editing making the news again after the recent Nobel Prize for CRISPR, China’s EdiGene has been raising new funds to accelerate its pipeline to the clinic, led by a potential one-time cure for thalassemia and helped by recent regulatory changes.
Given the high number of such trials in the country, China’s National Medical Products Administration has released separate guidelines for industry on the development of gene and cell therapies and gene editing clinical research.